| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Strategies for multivessel revascularization in patients with diabetes.
|
N Engl J Med
|
2012
|
10.79
|
|
2
|
Clinical judgment and treatment options in stable multivessel coronary artery disease: results from the one-year follow-up of the MASS II (Medicine, Angioplasty, or Surgery Study II).
|
J Am Coll Cardiol
|
2006
|
2.27
|
|
3
|
Comparative costs between myocardial revascularization with or without extracorporeal circulation.
|
Arq Bras Cardiol
|
2008
|
2.06
|
|
4
|
Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.
|
Circulation
|
2011
|
1.75
|
|
5
|
Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial.
|
Eur Heart J
|
2013
|
1.38
|
|
6
|
Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study.
|
J Am Coll Cardiol
|
2004
|
1.08
|
|
7
|
Effects of epinephrine in local dental anesthesia in patients with coronary artery disease.
|
Arq Bras Cardiol
|
2007
|
1.00
|
|
8
|
Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial.
|
Am Heart J
|
2013
|
0.91
|
|
9
|
Acute pleuropulmonary complications detected by computed tomography following myocardial revascularization.
|
Rev Hosp Clin Fac Med Sao Paulo
|
2002
|
0.90
|
|
10
|
Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study.
|
Coron Artery Dis
|
2008
|
0.86
|
|
11
|
Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease.
|
J Lipid Res
|
2002
|
0.85
|
|
12
|
Teratoma of the mediastinum: a case report.
|
J Med Case Rep
|
2011
|
0.85
|
|
13
|
Large bilateral coronary artery fistula: the choice of clinical treatment.
|
Arq Bras Cardiol
|
2009
|
0.85
|
|
14
|
Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial.
|
Int J Cardiol
|
2006
|
0.85
|
|
15
|
Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization.
|
Thromb Res
|
2007
|
0.84
|
|
16
|
Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study.
|
Coron Artery Dis
|
2009
|
0.84
|
|
17
|
Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.
|
J Thorac Cardiovasc Surg
|
2012
|
0.83
|
|
18
|
Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial.
|
Circulation
|
2012
|
0.83
|
|
19
|
Quality of life after surgical myocardial revascularization, angioplasty or medical treatment.
|
Arq Bras Cardiol
|
2007
|
0.83
|
|
20
|
Quality of life after on-pump and off-pump coronary artery bypass grafting surgery.
|
Arq Bras Cardiol
|
2008
|
0.82
|
|
21
|
Coronary to bronchial artery fistula: are we treating it right?
|
J Invasive Cardiol
|
2012
|
0.82
|
|
22
|
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
|
Diabetes Care
|
2012
|
0.82
|
|
23
|
Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study.
|
Circulation
|
2003
|
0.81
|
|
24
|
The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry.
|
Am Heart J
|
2012
|
0.80
|
|
25
|
Cancer-related deaths among different treatment options in chronic coronary artery disease: results of a 6-year follow-up of the MASS II study.
|
Coron Artery Dis
|
2012
|
0.80
|
|
26
|
[Thirty years of postgraduation in cardiology].
|
Arq Bras Cardiol
|
2006
|
0.79
|
|
27
|
The effects of glibenclamide, a K(ATP) channel blocker, on the warm-up phenomenon.
|
Ann Noninvasive Electrocardiol
|
2005
|
0.79
|
|
28
|
Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking.
|
Am J Cardiol
|
2004
|
0.78
|
|
29
|
[Electrocardiographic score: application in exercise test for the assessment of ischemic preconditioning].
|
Arq Bras Cardiol
|
2010
|
0.78
|
|
30
|
The cost-effectiveness of strategies in coronary artery disease.
|
Expert Rev Pharmacoecon Outcomes Res
|
2014
|
0.78
|
|
31
|
Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial.
|
Circulation
|
2012
|
0.78
|
|
32
|
Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease.
|
J Thorac Cardiovasc Surg
|
2009
|
0.77
|
|
33
|
I Diretriz sobre Aspectos Específicos de Diabetes (tipo 2) Relacionados à Cardiologia.
|
Arq Bras Cardiol
|
2014
|
0.76
|
|
34
|
Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
35
|
Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease.
|
Medicine (Baltimore)
|
2015
|
0.75
|
|
36
|
LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease.
|
Atherosclerosis
|
2002
|
0.75
|